entertainment -WSS

entertainment

author：fashion 2025-08-24 23:09:48 - browse：93

Jennifer Doudna Feng Zhang CRISPR — CRISPR pioneers Jennifer Doudna and Feng Zhang Illustration: STAT; Photos: AP, Getty

The revolution started in silence.

Jennifer Doudna and Emmanuelle Charpentier, now Nobelists, published their first paper announcing a new enzyme for editing DNA in Science in June 2012. It was called CRISPR-Cas9. It wasn’t until January 2013 that the first paper showing the enzyme would work in cells, from Feng Zhang, was published, also in Science. A similar paper from George Church came out at the same time.

No major media outlet covered the papers. The first story on CRISPR was published that March. But within the ivory tower of academia, it was clear something big was building, as requests for the technology poured in from other researchers and Zhang set up an assembly line in his laboratory to distribute it, with students carrying carefully packed samples to a FedEx office down the street.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Texas Medical Board asked to define abortion emergency exception

focus

WSS

Hospitals struggle to profit from CAR

Stanford president's case begs question: Who takes blame?

Readout LOUD: Venture capital, Gilead, and more M&A

AstraZeneca stays mum on Medicare drug pricing negotiations

Stanford president faces new allegations over 1999 paper

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

hotspot

entertainment

hotspot

Walensky prepares to leave CDC — and Congress — behind

DeSantis talks Trump, trans issues and 'what wokeness is'

Continuity nursing helped my family in our darkest PICU moments

Affordable Connectivity Program vital to health care, experts say

Virginia high school admissions case could be legal follow

Awakening the world to the whoosh: A patient's crusade

The cancer drug shortage isn’t new — and neither are the solutions

What’s missing from the debate over nursing home staff minimums

Guidelines to prevent youth baseball injuries need more muscle

Gene therapy for Afghan refugees’ infant will be fully covered

focus

Divers poised to search for children washed away in Pennsylvania flash flood

A protest over insulin prices is seen as a fight for life

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

7 more heat

Readout LOUD: Venture capital, Gilead, and more M&A

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

explore

explore

focus

hotspot